IP Library Granted Patent US 8,603,739
Granted Patent B2
US 8,603,739 · App. 12/551,115 · Granted Dec 10, 2013

Inhibitors of Rv0256c

Inventors: Sangita Mukhopadhyay (Andhra Pradesh, IN); Khalid Hussaid Bhat (Andhra Pradesh, IN); Nooruddin Khan (Andhra Pradesh, IN)
Assignee: Center for DNA Fingerprinting & Diagnostics
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,603,739
App. No.
12/551,115
Filed
Aug 31, 2009
Granted
Dec 10, 2013
Kind
B2
Art Unit
1645
USPC
435/6.1
Abstract

Described herein are methods for identifying inhibitors of Rv0256c functions, e.g., inhibitors of Rv0256c expression, DNA binding, nuclear localization and iNOS inhibition.

Claims (18)

1. A method of identifying a Rv0256c inhibitor comprising:

contacting a test agent with a eukaryotic cell expressing a Rv0256c polypeptide, wherein the Rv0256c polypeptide has a polypeptide sequence with at least about 75% sequence identity with the polypeptide sequence of SEQ ID NO:1; and

measuring one or more of:

(i) the level of Rv0256c mRNA or polypeptide expressed by the eukaryotic cell;

(ii) the level of nuclear localization of the Rv0256c polypeptide in the eukaryotic cell;

(iii) the level of nitric oxide produced by the eukaryotic cell; and

(iv) the level of inducible nitric oxide synthase (iNOS) expressed by the eukaryotic cell;

wherein a statistically significant decrease in (i) and/or (ii), or a statistically significant increase in (iii) and/or (iv), or any combination thereof, compared to a control eukaryotic cell not contacted with the test agent indicates that the test agent is an inhibitor of Rv0256c expression or function.

2. The method of claim 1 , wherein the expression level of the Rv0256c mRNA polypeptide is measured and a statistically significant decrease in the expression level of the Rv0256c polypeptide compared to a reference level of the Rv0256c polypeptide indicates that the test agent is a Rv0256c inhibitor.

3. The method of claim 2 , wherein the expression level of Rv0256c mRNA is measured using a quantitative northern blot, quantitative reverse transcription PCR (RT-PCR), or DNA microarray technologies.

4. The method of claim 2 , wherein the expression level of Rv0256c polypeptide is measured using a quantitative Western blot or fusing the Rv0256c polypeptide to a reporter gene.

5. The method of claim 1 , wherein the level of nuclear localization of the Rv0256c polypeptide is measured and a statistically significant decrease in the level of nuclear localization compared to a reference level of nuclear localization indicates that the test agent is a Rv0256c inhibitor.

6. The method of claim 1 , wherein the level of expression of inducible nitric oxide synthase (iNOS) is measured and an increase in the level of iNOS expression compared to a reference level of iNOS expression indicates that the test agent is a Rv0256c inhibitor.

7. The method of claim 1 , wherein the Rv0256c polypeptide comprises the polypeptide sequence of SEQ ID NO:1.

8. The method of claim 1 , wherein the test agent is selected from the group consisting of: a small molecule; a nucleic acid; a polypeptide; a lipid, and an antibody, or a fragment thereof.

9. The method of claim 1 , wherein measuring the level of nitric oxide produced by the cell comprises the use of Griess reagent.

10. The method of claim 1 , wherein the eukaryotic cell expresses the Rv0256c polypeptide as a result of transient transfection of the cell.

11. The method of claim 1 , wherein the eukaryotic cell is a macrophage.

Assignments (4)
RELEASE OF SECURITY INTEREST IN PATENTS, RECORDED ON JANUARY 29, 2019 AT REEL 048373 FRAME 0217 Recorded Sep 22, 2025
From: CRESTLINE DIRECT FINANCE, L.P., AS COLLATERAL AGENT
To: EMPIRE TECHNOLOGY DEVELOPMENT LLC
Reel/Frame 072936/0464 →
RELEASE OF SECURITY INTEREST Recorded Jul 31, 2019
From: CRESTLINE DIRECT FINANCE, L.P.
To: EMPIRE TECHNOLOGY DEVELOPMENT LLC
Reel/Frame 049924/0794 →
SECURITY INTEREST Recorded Jan 29, 2019
From: EMPIRE TECHNOLOGY DEVELOPMENT LLC
To: CRESTLINE DIRECT FINANCE, L.P.
Reel/Frame 048373/0217 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 15, 2010
From: MUKHOPADHYAY, SANGITA; BHAT, KHALID HUSSAIN; KHAN, NOORUDDIN
To: CENTER FOR DNA FINGERPRINTING & DIAGNOSTICS
Reel/Frame 024993/0838 →
Priority Claims (1)
IN 2936/CHE/2008 · Nov 25, 2008 · national
Continuity (1)
Related Publication 20100129809A1 · May 27, 2010